Skip to main content
Reproductive Biology and Endocrinology : RB&E logoLink to Reproductive Biology and Endocrinology : RB&E
. 2025 Nov 17;23:142. doi: 10.1186/s12958-025-01475-z

Hyperbaric oxygen therapy improves oocyte yield and embryo quality in poor ovarian responders: a pre-post cohort study

Wenjia Meng 1,#, Wanqiu Zhu 2,#, Ziyi Song 1, Ye Pan 1, Xiuye Xing 1, Jing Guo 1, Lihong Pang 1, Fanwei Meng 1, Ziye Zhang 1, Jiachen Li 3, Jing Yang 2,✉, Qun Lu 1,✉
PMCID: PMC12621376  PMID: 41250167

Abstract

Background

Poor ovarian response (POR) is characterized by low oocyte yield, poor embryo quality, high cycle cancellation rates during controlled ovarian stimulation, and poor pregnancy outcomes. This study aimed to evaluate the potential of hyperbaric oxygen therapy (HBOT) in improving ovarian response, enhancing oocyte retrieval and embryo quality, and identifying the optimal HBOT regimen for POR patients.

Methods

A pre-post cohort study included 41 women aged 20–45 with POR to compare oocyte yield and embryo quality pre-post HBOT. Restricted cubic spline (RCS) regression analyzed the relationship between HBOT and the number of oocytes. A generalized estimating equation (GEE) model assessed the impact of HBOT on oocytes, normal fertilization rate, and available embryos rate.

Results

Paired analysis revealed that HBOT significantly increased the number of oocytes, follicle output rate (FORT), follicle-to-oocyte index (FOI), two-pronuclear (2PN), available embryos, normal fertilization rate, and available embryos rate. A nonlinear relationship was found between HBOT sessions and oocyte number (P-nonlinear = 0.016), which showed the oocytes rose significantly after two HBOT sessions, plateaued at four to seven sessions, and showed no further increase beyond eight sessions.

Conclusions

Combining the controlled ovarian stimulation process with 4–7 sessions of HBOT could improve oocyte number and embryo quality in POR patients.

Trial registration

This is a pre-post cohort study. Clinical trial number: not applicable.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12958-025-01475-z.

Keywords: Hyperbaric oxygen therapy, Poor ovarian response, Embryo quality

Introduction

The global trend of delayed childbearing has become increasingly prevalent due to various socio-economic factors, including extended periods of education, career preferences, and the widespread use of contraceptives. Consequently, the demand for fertility treatments among older women is rising. Both ovarian reserve and oocyte quality decline with age, and even a short delay in initiating in vitro fertilization and embryo transfer (IVF-ET) significantly reduces the chances of live birth, particularly in older women [1]. Due to heterogeneous risk factors, the incidence of poor ovarian response (POR) during controlled ovarian stimulation (COS) has been reported to range from 5.6% to 35.1% [2], and has increased with the trend of delayed childbearing [3]. POR involves a poor response to gonadotropins, leading to fewer follicles and oocytes, increasing cycle cancellations, lower embryo quality, and then experiencing lower pregnancy rates per transfer and reducing cumulative pregnancy rates [4].

The diagnostic criteria for POR were first clarified by the Bologna criteria formulated in 2011 [5], followed by the patient prognosis-oriented Patient-Oriented Strategy Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria [6]. Due to the poor prognosis for patients with POR, there is an urgent need to explore new assisted therapies to improve oocyte quality and enhance the outcomes of assisted reproduction treatment (ART). Existing treatments, such as growth hormone, Coenzyme Q10 (Co Q10), and dehydroepiandrosterone (DHEA), have been proposed to improve the prognosis of POR patients. However, their effectiveness remains controversial, and their clinical outcomes have not been consistently favorable [4, 7].

Angiogenesis in the ovary is critical for the cyclic recruitment and exponential growth phase of follicles [8], which is locally regulated by angiogenic factors such as vascular endothelial growth factor (VEGF). Fisher et al. observed high concentrations of VEGF-A in rapidly growing follicles [9]. Enhanced angiogenesis facilitates the delivery of essential nutrients to the follicles, ultimately promoting oocyte growth. Hyperbaric oxygen therapy (HBOT) is a non-invasive technique that delivers 100% oxygen at higher-than-normal atmospheric pressure, thereby increasing the amount of oxygen dissolved in body tissues, including ovaries and follicles [10, 11]. This process promotes angiogenesis by stimulating key growth factors, such as VEGF. Additionally, HBOT induces a variety of benign cellular processes usually triggered by hypoxia through intermittent hyperoxic exposure, helping cells to develop tolerance to reactive oxygen species (ROS) and reducing cellular damage from oxidative stress [12, 13]. Oxidative stress is considered one of the essential pathogenic mechanisms of POR [14, 15]. Ma et al. found that oocyte maturation, fertilization, and blastocyst formation rates were improved in HBOT-treated aged mice [16]. Therefore, it is hypothesized that HBOT may enhance ART outcomes through its effects on oocyte retrieval and embryo quality, potentially benefiting patients with POR. This study aimed to investigate the role of HBOT in improving oocyte retrieval and embryo quality in POR patients. Additionally, the optimal number of HBOT sessions was explored.

Methods

Participants

This pre-post cohort study was conducted at the Medical Center for Human Reproduction, Beijing Chao-Yang Hospital, Beijing, China, from March 2024 to November 2024. After providing informed consent, female patients undergoing IVF-ET treatments who expressed interest in HBOT were included in the study. Ethical approval was obtained from the Institutional Review Board of Beijing Chao-Yang Hospital (Approval Number: 2024-SCI-953).

Inclusion Criteria were as follows: (1) Women aged between 20 and 45 years. (2) POR was diagnosed according to the Bologna criteria, which included age ≥ 40 years or other risk factors for poor ovarian response, ≤ 3 oocytes retrieved in a prior IVF cycle with the conventional ovulation regimen; and decreased ovarian reserve: antral follicle count (AFC) < 5–7 or anti-Müllerian hormone (AMH) < 0.5–1.1 ng/mL; POR was diagnosed when at least two of these three criteria [5]. (3) Body Mass Index (BMI) < 30 kg/m². (4) Underwent HBOT during the current oocyte pick-up (OPU) cycle.

Exclusion Criteria included: (1) History of recurrent miscarriage, repeated implantation failure, or uterine abnormalities. (2) Presence of chromosomal abnormalities in one or both partners. (3) Autoimmune diseases or other systemic conditions (e.g., hypertension, diabetes, cardiovascular diseases). (4) Medical contraindications to HBOT, including untreated pneumothorax, ongoing disulfiram therapy, or use of antineoplastic agents (e.g., bleomycin, cisplatin, doxorubicin). (5) Male partner diagnosed with severe oligospermia, asthenospermia, or teratozoospermia. A total of 41 patients who satisfied the inclusion and exclusion criteria underwent oocyte retrieval before and after HBOT. The flowchart detailing subject recruitment and inclusion is presented in Fig. 1.

Fig. 1.

Fig. 1

Flowchart of participant enrollment and inclusion. POR: poor ovarian response; IVF-ET: fertilization and embryo transfer; HBOT: hyperbaric oxygen therapy; BMI: body mass index; OPU: oocyte pick-up

COS process

Baseline characteristics, including age, BMI, AFC, duration and type of infertility, and baseline hormone levels, were recorded at enrollment. The appropriate COS regimen was individually selected based on ovarian reserve, clinical parameters such as BMI, and previous ovarian stimulation outcomes. COS protocols included mild stimulation protocol, antagonist protocol, progestin-primed ovarian stimulation (PPOS) protocol, and natural cycle protocol [17, 18]. Trigger time was determined by transvaginal ultrasound to assess follicular growth, or when the diameter of one to three follicles reached 17 mm, considering progesterone and estradiol levels. Follicular maturation was triggered by administering hCG or GnRH-agonists, or a combination of both. Oocyte retrieval was typically performed 36 h after the trigger.

The follicle output rate (FORT) was defined as the number of pre-ovulatory follicle with 16–22 mm diameters on the trigger day divided by the baseline AFC with 3–8 mm diameters, multiplied by 100 [17]. The follicle-to-oocyte index (FOI) was defined as the number of oocytes retrieved divided by the pre-treatment AFC multiplied by 100 [18]. Embryo laboratory parameters were also documented, comprising the number of mature oocytes, the number of two-pronuclear (2PN), and others. The embryo scoring criteria on day 3 were based on the Istanbul Consensus. Available embryos on day 3 were defined as those from fertilized oocytes, with at least 4 cells, a fragmentation rate of < 50%, and no multi-nucleation, developmental arrest, or blastomere cleavage. The good-quality embryos on day 3 were defined as cleavage-stage embryos with 7–9 blastomeres and a fragmentation rate of < 10%, originating from normally fertilized oocytes [19]. Blastocysts were evaluated using the Gardner and Schoolcraft scoring system. The number of blastocysts refers to those developed from normally fertilized oocytes, without considering blastocyst stage or quality. The good-quality blastocysts included those with stages ≥ 3 and grades AA, AB, BA, and BB [20]. The number of available embryos refers to the total number of embryos transferred and frozen, without differentiating between day 3 embryos and blastocysts.

Hyperbaric oxygen therapy

HBOT was initiated on day 3 of menstruation in conjunction with patients entering the COS cycle. HBOT was administered either every other day or daily up to the day before the trigger day. For patients willing to receive HBOT, the therapy was provided at the Hyperbaric Oxygen Department of Beijing Chao-Yang Hospital. Treatment was conducted in sizeable high-pressure air chambers (YC3700J-X, YC3200J-X, Hoto Oxygen Industrial, Shandong, China), targeting a pressure of 2.0 atmospheres absolute (ATA) with a total duration of 120 min. This included a 25–30 min pressurization phase, 60 min of pure oxygen inhalation at stable pressure, and a 30-minute decompression phase. Throughout the treatment, physicians closely monitored patients for any adverse reactions. The duration and sessions of HBOT were recorded.

Statistical analysis

Data were presented as mean ± SD or number (percentage). Paired data between two groups was analyzed using paired samples t-test, paired chi-square tests, and generalized estimation equation (GEE). Pairing data between three groups was analyzed using repeated measures ANOVA, Cochran’s Q test, and GEE. Comparisons between groups were made using ANOVA and chi-square tests. The effect of receiving HBOT on the number of oocytes retrieved, normal fertilization rate, and available embryos rate was assessed separately using GEE modeling. Restricted cubic spline (RCS) regression analysis was employed to evaluate the dose-response relationship between the number of HBOT sessions and the number of oocytes retrieved. Through the smooth connection of polynomial functions, RCS enabled the depiction of the dose-response relationship between continuous independent and dependent variables. A GEE model was used to assess the impact of HBOT sessions on the number of oocytes retrieved, normal fertilization rate, and available embryos rate. GEE was a statistical method suitable for analyzing repeated measures and longitudinal data, as it accounts for the correlations between multiple cycles within the same patient. All statistical analyses were conducted using R software (version 4.4.2), and a P-value of < 0.05 was considered statistically significant.

Results

Baseline characteristics of POR patients

Forty-one patients were included in this study, consisting of 41 OPU cycles before HBOT, 41 cycles following the initial HBOT, and 13 cycles after the second HBOT. Table 1 showed the baseline characteristics of the POR participants. The mean age was 39.90 ± 4.56 years, with 56.1% of patients aged ≥ 40 years old. On average, the participants had experienced 2.54 ± 1.34 cycles before HBOT. Importantly, ovarian reserve markers supported the POR diagnosis: 82.9% (34/41) had an AFC of less than 7, 65.9% (27/41) had an AMH level of less than 1.1 ng/mL, and 46.4% (19/41) had a basal follicle-stimulating hormone (FSH) level greater than 10 mIU/mL.

Table 1.

Baseline characteristics of participants

Variables Patients (n = 41)
Age (y) 39.90 ± 4.56
Age ≥ 40 years old (%) 23 (56.10)
OPU cycles before HBOT (n) 2.54 ± 1.34
BMI (kg/m2) 23.05 ± 4.57
AFC (n) 4.56 ± 2.46
AMH (ng/mL) 1.08 ± 0.82
Basal FSH (mIU/mL) 10.76 ± 5.41
Basal LH (mIU/mL) 4.62 ± 2.76
Basal E2 (pg/mL) 56.24 ± 55.15
Basal P (ng/mL) 0.77 ± 0.47
PRL (ng/mL) 11.24 ± 4.25
T (ng/mL) 0.29 ± 0.19
TSH (mIU/L) 2.12 ± 0.93
Infertility Duration (y) 2.99 ± 2.36
Infertility type (%)
 Primary Infertility 23 (56.10)
 Secondary Infertility 18 (43.90)

OPU Oocyte pick-up, HBOT Hyperbaric oxygen therapy, BMI Body mass index, AFC Antral follicle count, AMH Anti-müllerian hormone, FSH Follicle-stimulating hormone, LH Luteinizing hormone, E2 Estradiol, P progesterone, PRL Prolactin, T Testosterone, TSH Thyroid-stimulating hormone

The outcomes comparison pre-post HBOT treatment

A paired analysis of 41 patients was performed to compare ovarian stimulation and embryological outcomes pre-post HBOT (Table 2; Fig. 2). The interval between the last OPU cycle before HBOT and the first OPU cycle after HBOT was 3.27 ± 2.59 months, with a median of 2.90 months (Q25: 1.33, Q75: 5.17). Patients who underwent HBOT received an average of 4.46 ± 2.26 HBOT sessions. Pre-post HBOT, the number of pre-ovulatory follicles increased from 2.07 ± 1.57 to 3.00 ± 1.99 (P = 0.003), and the number of retrieved oocytes improved from 2.27 ± 2.25 to 3.63 ± 2.50 (P = 0.001).

Table 2.

Paired analysis of ovarian stimulation and embryological outcomes in OPU cycles pre-post HBOT

Variable Before HBOT
(n = 41)
After HBOT
(n = 41)
P-value
Interval between the latest pre- and first post-HBOT OPU cycle (month) - 3.27 ± 2.59
Number of HBOT sessions per OPU cycle - 4.46 ± 2.26
Ovarian stimulation protocol (%) 0.340
 Antagonist protocol 31 (75.61) 32 (78.05)
 Mild stimulation protocol 2 (4.88) 0 (0.00)
 Natural cycle protocol 3 (7.32) 1 (2.44)
 PPOS protocol 5 (12.20) 8 (19.51)
Initial Gn dose (IU) 256.40 ± 103.27 292.68 ± 78.81 0.022
Total Gn dose (IU) 2311.89 ± 1172.50 2699.38 ± 1169.96 0.179
Duration of stimulation (days) 7.46 ± 3.36 8.83 ± 2.84 0.068
E2 level on trigger day (pg/mL) 744.37 ± 729.09 808.03 ± 773.83 0.647
P level on trigger day (ng/mL) 2.22 ± 5.35 1.87 ± 2.12 0.712
LH level on trigger day (mIU/mL) 4.81 ± 4.74 3.96 ± 4.04 0.374
Trigger methods (%) 0.723
 GnRHa + hCG 26 (63.41%) 28 (68.29%)
 hCG 12 (29.27%) 9 (21.95%)
 GnRHa 3 (7.32%) 4 (9.76%)
Number of pre-ovulatory follicles on trigger day 2.07 ± 1.57 3.00 ± 1.99 0.003
FORT (%) 47.88 ± 38.68 72.74 ± 47.64 0.005
Number of oocytes retrieved 2.27 ± 2.25 3.63 ± 2.50 0.001
FOI (%) 49.04 ± 54.83 82.63 ± 53.43 0.006
Cycles with no retrieved oocytes (%) 9 (21.95) 0 (0) 0.002
Fertilization method (%) 0.003
 IVF 9 (28.12) 26 (63.41)
 ICSI 23 (71.88) 15 (36.59)
Number of MII oocytes 1.67 ± 2.67 2.40 ± 2.92 0.147
Oocyte maturation rate (%) 24.56 ± 35.53 52.70 ± 40.22 0.026
Number of 2PN 1.12 ± 1.40 2.20 ± 1.60 < 0.001
Normal fertilization rate (%) 42.23 ± 46.63 64.49 ± 32.24 0.015
Number of available embryos on day 3 1.07 ± 1.13 2.32 ± 1.88 < 0.001
Number of good-quality embryos on day 3 0.22 ± 0.52 0.78 ± 0.99 0.002
Rate of good-quality embryos on day 3 (%) 11.79 ± 28.93 31.24 ± 37.70 0.005
Number of blastocysts 0.22 ± 0.47 0.39 ± 0.63 0.089
Blastocyst formation rate (%) 15.85 ± 34.55 23.98 ± 40.32 0.253
Number of good-quality blastocysts 0.00 ± 0.00 0.12 ± 0.40 0.058
Rate of good-quality blastocysts (%) 0.00 ± 0.00 9.76 ± 30.04 0.044
Cycles with no available embryos (%) 24 (58.54) 6 (14.63) < 0.001
Number of available embryos 0.54 ± 0.71 1.49 ± 0.95 < 0.001
Available embryos rate (%) 32.52 ± 42.16 60.08 ± 35.70 0.003

The table presented a matched-pair analysis comparing the last OPU cycles before HBOT with the first after HBOT. Data were shown as mean ± SD or number (percentage). Paired t-tests were used for continuous variables, paired chi-square tests for binary variables, and GEE for unordered categorical variables

 HBOT Hyperbaric oxygen therapy, OPU Oocyte pick-up, PPOS Progestin-primed ovarian stimulation, Gn Gonadotropin, E2 Estradiol, P Progesterone, LH Luteinizing hormone, FORT Follicle output rate, FOI Follicle output index, 2PN Two-pronuclear

Fig. 2.

Fig. 2

Improvement in oocytes, 2PN, and available embryos after HBOT. The figure showed a matched-pair analysis comparing the number of oocytes, 2PN, and available embryos between the last OPU cycles before HBOT with the first after HBOT. 2PN: two-pronuclear; HBOT: hyperbaric oxygen therapy; OPU: oocyte pick-up

FORT and FOI were also significantly increased. The oocyte maturation rate, number of 2PN, the normal fertilization rate, number of good-quality embryos on day 3 and good-quality blastocysts, number of available embryos and available embryos rate, all significantly increased. In addition, twenty-four OPU cycles (58.54%) had no available embryos before HBOT, while six OPU cycles (14.63%) after HBOT (P < 0.001).

In addition, paired analyses about the last OPU cycle before HBOT with the first and second OPU cycles after HBOT for 13 patients were performed in Table S1. An increasing trend in AFC and a decreasing trend of basal FSH levels in the second OPU cycle after HBOT, though not statistically significant. Notably, the second OPU cycle showed the highest FORT, oocytes, FOI, oocyte maturation rate, number of MII oocytes, 2PN, available embryos on day 3, and blastocysts count among the three groups, with non-statistical significance. Furthermore, cycles of no available embryos gradually declined from the pre-HBOT cycle to the first and second oocyte retrieval cycles after HBOT (53.85% vs. 15.38% vs. 7.69%, P = 0.021).

Effect of HBOT on oocyte number and embryo quality

The GEE regression models were conducted to analyze the relationship between receiving HBOT and oocytes, normal fertilization rate, and available embryos rate (Table 3). Both unadjusted and adjusted models consistently demonstrated a significant increase in these parameters associated with HBOT. The results were consistent across adjusted model 1 (controlling for age, AMH, AFC, and BMI), model 2 (additionally adjusted for COS protocols), and model 3 (further adjusted for trigger methods), all showing significant improvements in oocyte number (β = 1.51, 95% CI: 0.92–2.10, P < 0.001 in model 3), normal fertilization rate (β = 17.23, 95% CI: 2.35–32.11, P = 0.023 in model 3), and available embryos rate (β = 24.29, 95% CI: 7.27–41.31, P = 0.005 in model 3) following HBOT.

Table 3.

Impact of HBOT on oocyte number and embryo quality using GEE analysis

Outcomes Unadjusted model Adjusted model 1 Adjusted model 2 Adjusted model 3
β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Oocyte (n) before HBOT Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
after HBOT 1.48 (0.78–2.18) < 0.001 1.44 (0.77–2.11) < 0.001 1.50 (0.88, 2.12) < 0.001 1.51 (0.92, 2.10) < 0.001
Normal fertilization rate (%) before HBOT Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
after HBOT 21.13 (4.22–38.04) 0.014 21.46 (4.35–38.57) 0.014 16.98 (1.45, 32.52) 0.032 17.23 (2.35, 32.11) 0.023
Available embryos rate (%) before HBOT Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
after HBOT 28.58 (12.32–44.84) < 0.001 28.34 (11.71–44.97) < 0.001 25.14 (8.79, 41.49) 0.003 24.29 (7.27, 41.31) 0.005

The results from GEE regression models assessed the impact of HBOT treatment on outcomes related to the oocyte, normal fertilization rate, and available embryos rate. The analysis included data from 41 OPU cycles before HBOT and 54 OPU cycles after HBOT, which included 41 cycles post-first HBOT and 13 cycles post-second HBOT

Adjusted model 1 was adjusted for age, AMH, AFC, and BMI as confounding factors. Adjusted model 2 was adjusted for age, AMH, AFC, BMI, and COS protocols as confounding factors. Adjusted model 3 was adjusted for age, AMH, AFC, BMI, COS protocols, and trigger methods as confounding factors

Abbreviations: GEE Generalized estimation equation, CI Confidence interval, HBOT Hyperbaric oxygen therapy, OPU Oocyte pick-up, AMH Anti-müllerian hormone, AFC Antral follicle count, BMI Body mass index, COS Controlled ovarian stimulation

Impact of HBOT sessions on oocyte number and embryo quality

To explore the dose-response relationship between the number of HBOT sessions and the number of oocytes retrieved, RCS analysis was conducted (Fig. 3). The model was adjusted for confounding factors such as age, AMH, AFC, BMI, COS protocols, and trigger methods. A nonlinear relationship was observed between the HBOT sessions and oocytes (P-nonlinear = 0.016, respectively). Specifically, the oocyte number increased significantly after two HBOT sessions, plateaued after four to seven sessions, and showed no further increase after eight or more sessions. Subsequently, different HBOT sessions were assessed using similar GEE regression models (Table S2). The 4–7 sessions group showed consistent and significant improvements in oocyte number, normal fertilization rate, and available embryos rate across all models (oocyte: β = 2.06, 95% CI: 1.24–2.87, P < 0.001; normal fertilization rate: β = 18.33, 95% CI: 3.04–33.61, P = 0.019; available embryos rate: β = 30.31, 95% CI: 11.87–48.74, P = 0.001 in adjusted model 3). The 8–10 sessions group also demonstrated significant gains in oocyte yield, although effect sizes decreased after adjustment, and improvements in normal fertilization rate and available embryos rate were not significant. The 1–3 sessions group showed limited effects, with only the normal fertilization rate reaching significance.

Fig. 3.

Fig. 3

Impact of HBOT sessions on oocyte using RCS analysis. The dose-response relationship between HBOT sessions and oocyte. The analysis included data from 54 OPU cycles after HBOT, which included 41 cycles post-first HBOT and 13 cycles post-second HBOT. The model was adjusted for age, AMH, AFC, BMI, COS protocols, and trigger methods as confounding factors. The red curves showed the regression lines with shading representing 95% confidence intervals. RCS: restricted cubic spline; HBOT: hyperbaric oxygen therapy; AMH: anti-müllerian hormone; AFC: antral follicle count; BMI: body mass index; COS: controlled ovarian stimulation

According to Fig. 3, to compare the effects of different numbers of HBOT sessions on the first OPU cycle after HBOT, the patients were divided into three groups based on the number of HBOT sessions: Group 1 (HBOT 1–3 sessions, n = 16), Group 2 (HBOT 4–7 sessions, n = 19), and Group 3 (HBOT 8–10 sessions, n = 6) (Table S3). Among the three groups, Group 2 had the significantly highest number of blastocysts and available embryos. Although Group 3 had the best ovarian reserve, it showed low oocyte retrieval, which is consistent with the findings in Fig. 3, indicating that receiving more than 8 sessions of HBOT may not be beneficial for oocyte retrieval.

Clinical pregnancy rates pre-post HBOT were 10%(1/10) and 5.3% (1/19). Patients who achieved clinical pregnancy using embryos from pre-HBOT cycles experienced early miscarriage. However, one patient maintained an ongoing pregnancy following HBOT. At the final follow-up, she was 40 + 2 weeks pregnant and delivered a healthy male infant vaginally, weighing 3620 g, with no maternal or fetal complications.

Discussion

This study demonstrated that receiving HBOT treatment in POR patients increased oocyte yield, improved ovarian response as reflected by FORT and FOI, and enhanced embryo quality, thereby improving their chances of achieving pregnancy. RCS and GEE analyses indicated that administering 4–7 HBOT sessions yielded optimal outcomes, significantly improving both oocyte yield and embryo quality. These findings supported a short, non-invasive HBOT combined with COS protocol as a promising option for the treatment of POR patients.

The follicles grow in the exponential growth phase, requiring significant angiogenesis to ensure an adequate supply of a wide range of nutrients, such as amino acids like methionine, lysine, arginine, and micronutrients [8]. Whole-organ imaging in mice revealed that ovarian vascular density and angiogenic intensity are closely related to follicular development. Particularly in aged mice, a marked reduction in ovarian vascular density and angiogenic intensity was observed, leading to insufficient ovarian blood supply and consequently impairing follicular development and maturation. Treatment with salidroside reversed ovarian aging and promoted ovarian angiogenesis, thereby improving fertility in aged female mice [21]. Therefore, it is hypothesized that impaired angiogenesis in older women and POR patients may reduce oocyte quantity and quality, which could be improved by enhancing vascularization.

In various diseases, HBOT has been demonstrated to enhance tissue blood flow and oxygen supply by promoting vascularization through intermittent hyperoxia, activation of hypoxia-inducible factor 1α (HIF-1α), and upregulation of VEGF expression [12, 22–24]. Moreover, HBOT has been shown to increase VEGF expression in follicular fluid [25]. These findings collectively suggest that HBOT promotes oogenesis by enhancing VEGF expression and increasing angiogenesis, thereby augmenting follicular blood flow and oxygen supply, which facilitates follicular development [9]. In the present study, POR patients after HBOT were found to have increased oocyte retrieval, FORT, and FOI compared to pre-HBOT OPU cycles. The enhanced FORT and FOI post-HBOT treatment reflected the improved dynamic follicular response to exogenous Gn, potentially linked to enhanced ovarian blood supply and optimized oocyte development microenvironment, which may improve clinical pregnancy outcomes. Therefore, these findings support HBOT as enhancing ovarian response in POR patients by improving FORT and FOI and increasing oocyte yield.

This study showed that HBOT significantly improved oocyte quality and embryo quality, as reflected by enhanced oocyte maturation, normal fertilization, and available embryos rates. This phenomenon was supported by a study in which Ma et al. demonstrated similar findings using HBOT in 40-week-old female mice [13]. These may result from HBOT optimizing the ovarian microenvironment through improved mitochondrial function and reduced oxidative stress. As for POR women, mitochondrial dysfunction and excessive accumulation of ROS due to oxidative stress affect oocyte chromosome integrity and IVF outcome [14, 15, 26–29]. Repeated hyperoxia from HBOT activates pathways such as HIF-1 and SIRT1, limiting ROS overproduction and promoting mitochondrial biogenesis and ATP production [13, 30–33], which improves oocyte maturation, normal fertilization rate, and embryo quality for POR women.

The present study revealed a nonlinear dose-response relationship between HBOT sessions and treatment outcomes, with an optimal window of 4–7 sessions in one cycle. Previous studies have reported that moderate HBOT characterized by intermittent exposure to hyperoxia, can induce beneficial cellular processes similar to those triggered by hypoxia, thereby mitigating cellular damage from oxidative stress [12, 13]. In our study, HBOT sessions of 3 or fewer showed a trend toward increased oocyte yield, which plateaued at four to seven sessions, likely due to insufficient enhancement of tissue oxygenation with fewer sessions. Conversely, administering eight or more HBOT sessions may induce oxygen toxicity. It was also shown in Table S3, Group 3 (8–10 HBOT sessions) demonstrated a good ovarian reserve, yet produced poor oocyte and embryo yields. Similarly, Van Voorhis B J et al. reported a high cycle cancellation rate (5/10; 50%) for POR patients, who received daily HBOT from the start of ovarian stimulation until the day before OPU [25]. Therefore, we recommend that patients receive HBOT either every other day or every day before the trigger day to maintain the optimal oxygen concentration for oocyte development and maturation.

The mean age in this study was 39.90 ± 4.56 years, with an average interval of 3.27 ± 2.59 months between the last OPU cycle before HBOT and the first OPU cycle after HBOT, while ovarian reserve would decline progressively for POR women [34]. Notably, after HBOT, both the number of pre-ovulatory follicles and oocytes increased significantly. In comparison, other interventions aimed at improving soutcomes in POR patients require prolonged pre-treatment: growth hormone needs to be administered at least 4 weeks in advance [35], Co Q10 requires 2 months to exert an effect [36], and DHEA also necessitates approximately 1–3 months of pre-treatment [37]. In contrast, HBOT offers the advantages of rapid onset and pronounced efficacy, requiring no pre-treatment and can be initiated immediately upon the start of the COS cycle.

To our knowledge, this is the first pre-post cohort demonstrating the positive effects of HBOT for POR patients and determining the optimal number of short, non-invasive HBOT sessions. Nonetheless, several limitations should be noted. First, it was an exploratory study, and the small sample size limited the statistical power, particularly for subgroup analyses. Furthermore, there was no concurrent control group, such as POR patients receiving standard care without HBOT. Future studies should increase sample size and conduct prospective randomized controlled trials (RCTs) for more robust results, as well as to evaluate long-term outcomes, including pregnancy rates and offspring health. Additionally, although each patient was advised to undergo daily or alternate-day HBOT during the COS period until the day before the trigger, the actual timing and frequency of HBOT during this period were based on the individual preferences of the patient and were not strictly controlled or randomly assigned. Besides, our study suggested a promising potential for HBOT in improving the prognosis of POR patients. Moreover, mechanistic studies are required to elucidate the molecular pathways by which HBOT enhances embryo development.

In conclusion, this study demonstrated that HBOT significantly improved oocytes retrieved and embryo quality in POR patients, with the optimal treatment range of 4–7 sessions. These findings offer preliminary evidence supporting the potential utility of HBOT for POR patients.

Supplementary Information

Supplementary Material 1 (39.9KB, docx)

Acknowledgements

The authors thank the Medical Center for Human Reproduction and the Department of Hyperbaric Oxygen at Beijing Chao-Yang Hospital for their assistance with data collection.

Abbreviations

AFC

Antral follicle count

AMH

Anti-müllerian hormone

ART

Assisted reproduction treatment

BMI

Body mass index

Co Q10

Coenzyme Q10

COS

Controlled ovarian stimulation

DHEA

Dehydroepiandrosterone

FSH

Follicle-stimulating hormone

FORT

Follicle output rate

FOI

Follicle-to-oocyte index

GEE

Generalized estimating equation

HBOT

Hyperbaric oxygen therapy

HIF-1α

Hypoxia-inducible factor 1 alpha

IVF-ET

In vitro fertilization and embryo transfer

2PN

Two-pronuclear

POR

Poor ovarian response

POSEIDON

Patient-Oriented Strategy Encompassing IndividualizeD Oocyte Number

RCS

Restricted cubic spline

ROS

Reactive oxygen species

VEGF

Vascular endothelial growth factor

Authors’ contributions

WJM and WQZ conceived and designed this article, completed the first draft, collected the clinical data, and conducted the preliminary analysis. FWM and ZYZ coordinated clinical data collection and statistics. ZYS, YP, XYX, JG, LHP, JY, JCL, and QL reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Key Technology Research and Development Program of China (grant numbers 2022YFC2704404 and 2022YFC2704405) and the Beijing Chaoyang Hospital Multidisciplinary Clinical Research Innovation Team Project (CYDXK202203).

Data availability

No datasets were generated or analyzed during the current study.

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from the Institutional Review Board of Beijing Chao-Yang Hospital (Approval Number: 2024-SCI-953). All participants provided written informed consent. The study adhered to the ethical standards of the World Medical Association’s Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Wenjia Meng and Wanqiu Zhu have equal contributions to this work.

Contributor Information

Jing Yang, Email: yangjinghbo@163.com.

Qun Lu, Email: luqun1023@sina.com.

References

  • 1.Liang Y, Huang J, Zhao Q, Mo H, Su Z, Feng S, et al. Global, regional, and national prevalence and trends of infertility among individuals of reproductive age (15–49 years) from 1990 to 2021, with projections to 2040. Hum Reprod. 2025;40:529–44. [DOI] [PubMed] [Google Scholar]
  • 2.Zhang Y, Zhang C, Shu J, Guo J, Chang H-M, Leung PCK et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2019;26:247–63. Available from: https://www.semanticscholar.org/paper/abf2cfe920641ff168749577429cbdc0d94ed1f2 [DOI] [PubMed]
  • 3.Lebovitz O, Haas J, Mor N, Zilberberg E, Aizer A, Kirshenbaum M, et al. Predicting IVF outcome in poor ovarian responders. BMC Womens Health. 2022. 10.1186/s12905-022-01964-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zhu F, Yin S, Yang B, Li S, Feng X, Wang T, et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023. 10.1186/s12958-023-01119-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of poor response to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–24. [DOI] [PubMed] [Google Scholar]
  • 6.Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105:1452–3. [DOI] [PubMed] [Google Scholar]
  • 7.Mourad A, Jamal W, Hemmings R, Tadevosyan A, Phillips S, Kadoch I-J. Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial. Hum Reprod. 2024;40:77–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xu X, Mu L, Li L, Liang J, Zhang S, Jia L, et al. Imaging and tracing the pattern of adult ovarian angiogenesis implies a strategy against female reproductive aging. Sci Adv. 2022. 10.1126/sciadv.abi8683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fisher TE, Molskness TA, Villeda A, Zelinski MB, Stouffer RL, Xu J. Vascular endothelial growth factor and angiopoietin production by primate follicles during culture is a function of growth rate, gonadotrophin exposure and oxygen milieu. Hum Reprod. 2013;28:3263–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fischer I, Barak B. Molecular and therapeutic aspects of hyperbaric oxygen therapy in neurological conditions. Biomolecules. 2020;10:1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.De Wolde SD, Hulskes RH, Weenink RP, Hollmann MW, Van Hulst RA. The effects of hyperbaric oxygenation on oxidative stress, inflammation and angiogenesis. Biomolecules. 2021;11:1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hadanny A, Efrati S. The hyperoxic-hypoxic paradox. Biomolecules. 2020;10:958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fu Q, Duan R, Sun Y, Li Q. Hyperbaric oxygen therapy for healthy aging: from mechanisms to therapeutics. Redox Biol. 2022;53:102352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Luddi A, Capaldo A, Focarelli R, Gori M, Morgante G, Piomboni P, et al. Antioxidants reduce oxidative stress in follicular fluid of aged women undergoing IVF. Reprod Biol Endocrinol. 2016. 10.1186/s12958-016-0184-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tatone C, Amicarelli F, Carbone MC, Monteleone P, Caserta D, Marci R, et al. Cellular and molecular aspects of ovarian follicle ageing. Hum Reprod Update. 2008;14:131–42. [DOI] [PubMed] [Google Scholar]
  • 16.Ma Y, Zhong Y, Chen X, Liu H, Shi Y, Zhang X, et al. Hyperbaric oxygen treatment ameliorates the decline in oocyte quality and improves the fertility of aged female mice. Reprod Sci. 2022;30:1834–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gallot V, Berwanger da Silva AL, Genro V, Grynberg M, Frydman N, Fanchin R. Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the follicular output rate (FORT) May predict in vitro fertilization-embryo transfer outcome. Hum Reprod. 2012;27:1066–72. [DOI] [PubMed] [Google Scholar]
  • 18.Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S et al. Understanding Ovarian Hypo-Response to Exogenous Gonadotropin in Ovarian Stimulation and Its New Proposed Marker—The Follicle-To-Oocyte (FOI) Index. Front Endocrinol. 2018;9. Available from: https://www.semanticscholar.org/paper/5baf04003369ca62a367bb9d85cc764c9e590012 [DOI] [PMC free article] [PubMed]
  • 19.Group of Embryology AS in RM and, Balaban ESI, Brison B, Calderon D, Catt G, Conaghan J et al. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26:1270–83. [DOI] [PubMed]
  • 20.Schoolcraft WB, Gardner DK, Lane M, Schlenker T, Hamilton F, Meldrum DR. Blastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programs. Fertil Steril. 1999;72:604–9. Available from: https://www.semanticscholar.org/paper/275a09aba7e0b4695825734499f5cdc31e501df0 [DOI] [PubMed]
  • 21.Mu L, Wang G, Yang X, Liang J, Tong H, Li L, et al. Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. Nat Commun. 2025. 10.1038/s41467-024-55509-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Huang X, Liang P, Jiang B, Zhang P, Yu W, Duan M, et al. Hyperbaric oxygen potentiates diabetic wound healing by promoting fibroblast cell proliferation and endothelial cell angiogenesis. Life Sci. 2020;259:118246–118246. [DOI] [PubMed] [Google Scholar]
  • 23.Yamamoto N, Oyaizu T, Enomoto M, Horie M, Yuasa M, Okawa A, et al. VEGF and bFGF induction by nitric oxide is associated with hyperbaric oxygen-induced angiogenesis and muscle regeneration. Sci Rep. 2020. 10.1038/s41598-020-59615-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Cannellotto M, Yasells García A, Landa MS. Hyperoxia: effective mechanism of hyperbaric treatment at mild-pressure. Int J Mol Sci. 2024;25:777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Van Voorhis BJ, Greensmith JE, Dokras A, Sparks AET, Simmons ST, Syrop CH. Hyperbaric oxygen and ovarian follicular stimulation for in vitro fertilization: a pilot study. Fertil Steril. 2005;83:226–8. [DOI] [PubMed] [Google Scholar]
  • 26.Palini S, Benedetti S, Tagliamonte MC, De Stefani S, Primiterra M, Polli V et al. Influence of ovarian stimulation for IVF/ICSI on the antioxidant defence system and relationship to outcome. Reprod Biomed Online. 2014;29:65–71. Available from: https://www.semanticscholar.org/paper/c13f6413f60c3d3cac693e8c21d6a98244821dbf [DOI] [PubMed]
  • 27.Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Integr Comp Physiol. 2007;292:R18-36. [DOI] [PubMed] [Google Scholar]
  • 28.Shen L, Liu J, Luo A, Wang S. The stromal microenvironment and ovarian aging: mechanisms and therapeutic opportunities. J Ovarian Res. 2023. 10.1186/s13048-023-01300-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Smits MAJ, Schomakers BV, van Weeghel M, Wever EJM, Wüst RCI, Dijk F, et al. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction. Hum Reprod. 2023;38:2208–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Suzuki J. Endurance performance is enhanced by intermittent hyperbaric exposure via up-regulation of proteins involved in mitochondrial biogenesis in mice. Physiol Rep. 2017;5:e13349–e13349. Available from: https://www.semanticscholar.org/paper/3c607df193d5c81d6d896c54aaedc1e035eb731f [DOI] [PMC free article] [PubMed]
  • 31.Sakas R, Dan K, Edelman D, Abu-Ata S, Ben-Menashe A, Awad-Igbaria Y, et al. Hyperbaric oxygen therapy alleviates memory and motor impairments following traumatic brain injury via the modulation of Mitochondrial-Dysfunction-Induced neuronal apoptosis in rats. Antioxidants. 2023;12:2034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Oscarsson N, Ny L, Mölne J, Lind F, Ricksten S-E, Seeman-Lodding H, et al. Hyperbaric oxygen treatment reverses radiation induced pro-fibrotic and oxidative stress responses in a rat model. Free Radic Biol Med. 2017;103:248–55. [DOI] [PubMed] [Google Scholar]
  • 33.Zhang Q, Gould LJ. Hyperbaric oxygen reduces matrix metalloproteinases in ischemic wounds through a redox-dependent mechanism. J Invest Dermatol. 2014;134:237–46. [DOI] [PubMed] [Google Scholar]
  • 34.Velde ERte. The variability of female reproductive ageing. Hum Reprod Update. 2002;8:141–54. [DOI] [PubMed] [Google Scholar]
  • 35.Gong Y, Zhang K, Xiong D, Wei J, Tan H, Qin S. Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial. Reprod Biol Endocrinol. 2020. 10.1186/s12958-020-00648-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod Biol Endocrinol. 2018. 10.1186/s12958-018-0343-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhang J, Jia H, Diao F, Ma X, Liu J, Cui Y. Efficacy of dehydroepiandrosterone priming in women with poor ovarian response undergoing IVF/ICSI: a meta-analysis. Front Endocrinol. 2023. 10.3389/fendo.2023.1156280. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (39.9KB, docx)

Data Availability Statement

No datasets were generated or analyzed during the current study.


Articles from Reproductive Biology and Endocrinology : RB&E are provided here courtesy of BMC

RESOURCES